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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow
limitation and airway inflammation, accompanied by decreased health status. It is still unknown which
factors are responsible for the impaired health status in COPD. We postulated that airway inflammation
negatively contributes to health status in COPD.
Methods: In 114 COPD patients (99 male, age: 62 ± 8 yr, 41 [31–55] pack-years, no inhaled or oral
corticosteroids, postbronchodilator FEV1: 63 ± 9% pred, FEV1/IVC: 48 ± 9%) we obtained induced sputum
and measured health status (St. George's respiratory questionnaire (SGRQ)), postbronchodilator FEV1,
hyperinflation (RV/TLC), and airway hyperresponsiveness to methacholine (PC20). Sputum was induced by
hypertonic saline and differential cell counts were obtained in 102 patients.
Results: Univariate analysis showed that SGRQ total and symptom score were positively associated with
% sputum macrophages (r = 0.20, p = 0.05; and r = 0.20, p = 0.04, respectively). Multiple regression analysis
confirmed these relationships, providing significant contributions of % sputum macrophages (B = 0.25, p =
0.021) and RV/TLC (B = 0.60, p = 0.002) to SGRQ total score. Furthermore, SGRQ symptom score was
associated with % sputum macrophages (B = 0.30, p = 0.03) and RV/TLC (B = 0.48, p = 0.044), whilst
SGRQ activity score was associated with % sputum macrophages (B = 0.46, p = 0.002), RV/TLC (B = 0.61,
p = 0.015), and PC20 (B = -9.3, p = 0.024). Current smoking and FEV1 were not significantly associated with
health status in the multiple regression analysis.
Conclusion:  We conclude that worse health status in COPD patients is associated with higher
inflammatory cell counts in induced sputum. Our findings suggest that airway inflammation and
hyperinflation independently contribute to impaired health status in COPD. This may provide a rationale
for anti-inflammatory therapy in this disease.
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Background
Chronic obstructive pulmonary disease (COPD) is a
major and growing cause of morbidity and mortality
[1,2]. It is characterized by progressive and not fully
reversible airflow limitation, as measured with the forced
expiratory volume in one second (FEV1). The airflow lim-
itation is associated with a chronic inflammatory process
in the airways and lung parenchyma in response to nox-
ious particles or gases, in particular tobacco smoking
[1,2].
In daily life COPD patients are bothered by airway symp-
toms such as dyspnea, cough and sputum production
[2,3]. This is accompanied by a serious decrease of health
status [4]. Several studies have attempted to link health
status to the severity of airflow limitation in patients with
COPD [4] and show that the relationship is at best a loose
one. Even the largest study assessing health status by the
St. George's respiratory questionnaire (SGRQ) provides
only weak associations with the degree of airflow limita-
tion, as measured by FEV1 [5,6]. This suggests that other
factors additionally contribute to the health status in
COPD. One of those may be dynamic hyperinflation, i.e.
increased residual volume and total lung capacity [7], pos-
sibly as a consequence of chronic inflammation and
restructuring of the airways and/or parenchyma [8,9].
The chronic inflammatory process in COPD is character-
ized by infiltration of the airways by neutrophils, macro-
phages and CD8-positive T cells [10,11]. Such features of
inflammation in COPD are likely driven by various cellu-
lar pathways, including pro-inflammatory cytokines and
mediators of oxidative stress [12,13]. These cytokines and
mediators may not only be responsible for local airway
inflammation but can also induce features of systemic
inflammation in COPD [14-16]. The latter is assumed to
be linked with impaired functional status in COPD [12],
just as it has been shown in other chronic inflammatory
conditions such as bronchiectasis, rheumatoid arthritis,
chronic end-stage renal disease and inflammatory bowel
syndrome [17,18]. Hence, it is not unlikely that the
underlying local airway inflammation in COPD can drive
impairment of health status as well [12].
We hypothesized that health status in COPD is affected by
the severity of airway inflammation. The aim of our study
was to test this hypothesis in a large cross-sectional study
by assessing the relationship between airway inflamma-
tion, as measured by cell counts in induced sputum, and
health status in COPD. In order to examine the independ-
ent effects of airway inflammation, the influence of clini-
cal disease markers such as smoking, lung function,
hyperinflation and airways hyperresponsiveness on
health status was included.
Some of the results of this study has been previously reported in
the form of an abstract [19].
Methods
Detailed information about subjects and methodology
has been published previously [20]. In brief, 114 patients
with COPD were included for the Groningen Leiden Uni-
versities Chronic Obstructive Lung Disease (GLUCOLD)
Study. Patients (45–75 years, current or ex-smokers ≥10
pack-years) had at least one of the following symptoms:
chronic cough, sputum production, or dyspnea on exer-
tion. Postbronchodilator forced expiratory volume in one
second (FEV1) was > 1.3 liter and > 20% predicted and
below the 90% confidence interval of the predicted
FEV1[21]. Postbronchodilator FEV1/IVC ratio was below
the 90% confidence interval of the predicted FEV1/IVC
ratio. These lung function levels are compatible with
GOLD stages II and III [2]. Patients were clinically stable
for more than 2 months and free of common cold symp-
toms for 2 weeks before the measurements. They did not
use a course of inhaled or oral corticosteroids during the
past 3 months prior to randomization and did not have
maintenance treatment with these drugs during the past 6
months. Patients with considerable co-morbidity were
excluded. Usage of short-acting bronchodilators was
allowed during the study. Each center's local medical eth-
ics committee approved the protocol and patients pro-
vided written informed consent.
This study represents a cross-sectional analysis of baseline
data from the GLUCOLD Study. Health status was meas-
ured using the St. George's respiratory questionnaire [22].
This is a well-validated, standardized, self-administered
questionnaire, specifically designed for respiratory dis-
eases. It contains 50 items and is divided into three sec-
tions: symptoms (distress caused by respiratory
symptoms), activity (physical activities that cause or are
limited by breathlessness), and impact (social and psy-
chological effects of the disease). The total score and the
three separate component scores were calculated. The
scores range from zero to 100, where zero indicates best
and 100 represents worst health status.
Sputum was induced and processed according to a vali-
dated technique [23]. After inhaling 200 μg salbutamol
the patients inhaled hypertonic sodium chloride aerosols
(4.5 w/v %) during 3 periods of 5 min. Whole sputum
samples were processed within two hours from sputum
induction. Differential cell counts were expressed as a per-
centage of nucleated cells, excluding squamous cells. A
sputum sample was considered adequate when the per-
centage squamous cells was less than 80% [23].
Spirometry was performed, according to international
guidelines [24], using the Quanjer reference values [21].Respiratory Research 2006, 7:140 http://respiratory-research.com/content/7/1/140
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Total lung capacity (TLC) and residual volume (RV) were
measured using a constant volume bodyplethysmograph
[21]. Airway hyperresponsiveness was determined using
the 2-minute tidal breathing method [25] and expressed
as the provocative concentration causing a 20% fall in
FEV1 (PC20). The diffusion capacity for carbon monoxide
per liter alveolar volume (KCO) was measured using the
single breathholding method [26]. The associations of the
SGRQ total, symptom, activity and impact scores with
inflammatory cell counts and various other study varia-
bles were examined using Pearson's and Spearman's rank
correlation. Differences between smokers and ex-smokers
were analyzed with the Student t test and Mann Whitney
U. Skewed data (pack-years, PC20, % and numbers of
inflammatory cells in sputum) were transformed when
appropriate. Multiple linear regression analyses (ENTER
method) were performed to assess the relation between
health status (SGRQ total, symptom, activity and impact
scores) and sputum inflammatory cell counts, independ-
ent of age, gender, current smoking, postbronchodilator
FEV1, RV/TLC, and PC20. Probability values of ≤0.05 were
considered significant. All analyses were performed using
the Statistical Package for Social Sciences (SPSS)-12.
Results
Characteristics
A total of 114 patients were enrolled in the study. Patient
characteristics have been published in extensive detail
[20]. In short, most patients (87%) were middle-aged
males (mean ± standard deviation (SD) 62% ± 8). They
had a median of 41 pack-years of smoking, 37% being ex-
smokers. Patients had moderate to severe COPD as based
on their postbronchodilator FEV1 (mean ± SD 63% ± 9 of
predicted (pred)) and exhibited a wide range in RV/TLC
(mean ± SD 48 ± 8) and PC20 (geometric mean, inter quar-
tile range (IQR) 0.6 [0.17–2.40]). A total of 110 patients
adequately completed the SGRQ and 102 from these were
able to produce an acceptable sputum sample. Data from
the 102 patients were used for all analyses. The median
SGRQ scores were indicative of moderately impaired
health status (table 1). Number and differential counts of
sputum cells are shown in table 2.
Univariate analysis
The total and symptom scores were positively associated
with % macrophages (r = 0.20, p = 0.050; and r = 0.20, p
= 0.041, respectively). The univariate relationship
between the SGRQ scores and sputum inflammatory cell
counts is shown in table 3. The regression coefficient (B)
in table 3 represents the strength of the association. Our
results show that an increase in sputum macrophages of
1% is associated with an increase of the mean total score
of 0.22 point. In addition, figure 1 shows the effect-size of
a higher percentage of sputum macrophages on the SGRQ
scores. Patients with <15% sputum macrophages have a
mean total score of 27. The total score is on average 5
points higher in patients with 15–45% sputum macro-
phages, and 9 points higher in patients with > 45% spu-
tum macrophages. A significant threshold of four units in
SGRQ scores may be considered as clinically relevant [27].
The activity and impact scores were not significantly asso-
ciated with sputum % macrophages (r = 0.19, p = 0.061;
rs = 0.14, p = 0.16, respectively). No significant associa-
tions were found between all SGRQ scores and percent-
ages of neutrophils, eosinophils, lymphocytes, epithelial
cells, nor with absolute numbers of total sputum cells,
neutrophils, macrophages, lymphocytes, and epithelial
cells.
With regard to clinical and functional parameters, the
total, symptom and impact scores were higher among
smokers, as compared with ex-smokers (median total
score = 33.2 vs 25.8, p = 0.040; median symptom score =
46.8 vs 40.9, p < 0.01; median impact score = 19.7 vs 11.3,
p = 0.023, for smokers and ex-smokers, respectively).
Higher symptom scores were associated with a larger
amount of pack-years (r = 0.29, p < 0.01). Higher activity
scores were associated with lower postbronchodilator
FEV1 (r = -0.24, p = 0.017), increased lung hyperinflation,
as assessed by RV/TLC ratio (r = 0.25, p = 0.012) and less
hyperresponsiveness, as assessed by PC20 (r = -0.22, p =
0.033). No associations were found between any of the
SGRQ scores and CO-diffusion capacity, as assessed by
KCO (data not shown).
Multiple regression analysis
Multiple regression analysis confirmed the relationship
between SGRQ total score and % sputum macrophages (B
= 0.25, p = 0.021), with an explained variance of 14%. In
this model there was a significant contribution of RV/TLC
(B = 0.60, p = 0.002). Age, current smoking, gender, post-
bronchodilator FEV1, or PC20 were not significantly asso-
ciated with the total score in this model. The symptom
domain also remained significantly associated with %
sputum macrophages in the multiple regression analysis
(B = 0.30, p = 0.03), together with RV/TLC (B = 0.48, p =
0.044). Finally, multiple regression analysis showed a
relationship between the activity score and % sputum
macrophages (B = 0.46, p = 0.002), again with a signifi-
cant contribution of RV/TLC (B = 0.61, p = 0.015) and
also with PC20 (B = -9.3, p = 0.024).
Discussion
This study demonstrates that health status in COPD is
associated with inflammatory cell counts in induced spu-
tum. The larger the percentage of sputum macrophages
was, the more impaired a patient's health status was. This
relationship was marginally modulated by the severity of
hyperinflation and airways hyperresponsiveness. TheseRespiratory Research 2006, 7:140 http://respiratory-research.com/content/7/1/140
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findings suggest that airway inflammation independently
contributes to impaired health status in COPD.
The novelty of this study is that we observed a relationship
between health status and inflammatory cell counts in
induced sputum in steroid naive, clinically stable patients
with moderately severe COPD. In general, health status
was markedly impaired, as indicated by a median SGRQ
total score of 32 [5]. Interestingly, our data suggest that
the inflammatory process is a stronger determinant of
health status than physiological measures of hyperinfla-
tion or airflow limitation. After taking percentage sputum
macrophages into account, only RV/TLC demonstrated a
consistent association with the total score and sub-
domains of the SGRQ. This points towards an independ-
ent role of hyperinflation among the determinants of
health status. Indeed, patients with a relatively high
degree of hyperinflation are known to have increased
breathlessness and reduced physical activities, which is
even more pronounced during exercise [28,29]. This is
likely to affect health status, especially with regard to the
activities domain. In addition, we found some evidence of
a contribution of airway hyperresponsiveness, which
extends previous observations in the general population
[30,31]. Although smoking is associated with health sta-
tus, our results show that the relationship between health
status and sputum percentages macrophages, within
patients with COPD, is similar in smokers as compared
with ex-smokers.
Our patient selection and methods seem to be appropri-
ate for the current study. The sample size of 102 patients
with a complete data set provided sufficient data for mul-
tivariate analysis. In general, some relationships might
have been arisen by chance given the potential for multi-
ple comparisons. However, the univariate associations
between inflammatory cell counts and health status
found in this study remained statistically significant when
adjusted for other relevant parameters using multiple
regression analysis, suggesting an independent and con-
sistent role for inflammation with regard to health status
in patients with COPD. Patients with clinically relevant
co-morbidity were excluded. We reasoned that marked co-
morbidity additionally affects disease-specific health sta-
tus [32], which could potentially introduce confounders.
We excluded all patients with maintenance therapy of
inhaled corticosteroids during the last six months.
Inhaled corticosteroids influence the inflammatory cell
counts in induced sputum in patients with COPD [33,34],
which easily might have disturbed any disease-related
associations between the inflammatory process and
health status.
How can we explain the observed positive association
between the percentage macrophages in sputum and
health status? In previous studies, neutrophils have been
linked to the severity of COPD, as measured with FEV1
[35]. In a previous report from our study group Lapperre
et el. categorized various functional and inflammatory fea-
tures of COPD into separate complementary domains
using a different statistical analysis, a so-called factor anal-
ysis. This revealed that FEV1 and neutrophilic inflamma-
tion are complementary dimensions that characterize
patients with COPD [20]. However, several studies sug-
gest a central role for macrophages in inflammatory proc-
esses and structural changes in the lung of patients with
COPD [36,37]. Chemokines, such as monocyte chemoat-
tractant protein 1 (MCP-1) and its receptor C-C chemok-
Table 1: St. George's respiratory questionnaire (SGRQ): median scores (n = 102).
Median [IQR]
Total SGRQ score 32 [19–43]
Symptom SGRQ score 44 [34–55]
Activity SGRQ score 42 [23–54]
Impact SGRQ score 18 [8.0–30]
The SGRQ scores from 102 patients with adequate questionnaires and sputa. Data are presented as median [inter-quartile range (IQR)]. Higher 
SGRQ scores indicate worse health status: 0 = best, 100 = worse.
Table 2: Inflammatory cells in induced sputum (n = 102).
Absolute numbers (104/ml) Percentage
Total cell count 135.0 [76.8–311.3] -
Neutrophils 99.2 [46.7–228.6] 72.6 [59.5–82.2]
Macrophages 32.3 [17.9–61.1] 22.8 [14.8–33.3]
Eosinophils 1.4 [0.3–4.8] 1.1 [0.3–2.2]
Lymphocytes 2.1 [1.0–6.8] 1.7 [1.2–2.3]
Epithelial cells 1.3 [0.6–3.8] 1.0 [0.3–2.3]
Data are presented as median [IQR]. Total cell count refers to the total number of non-squamous cells in sputum.Respiratory Research 2006, 7:140 http://respiratory-research.com/content/7/1/140
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Table 3: Association between sputum cell differential counts and health status assessed with SGRQ (n = 102), results from linear 
regression analyses.
SGRQ total score symptom score activity score impact score
Total cell count† B (95% CI) -1.7 (-8.0 to 4.6) -4.6 (-12 to 3.4) -0.74 (-9.2 to 7.7) -1.1 (-7.3 to 5.1)
% Neutrophils B (95% CI) -0.17 (-0.36 to 0.02) -0.20 (-0.44 to 0.04) -0.24 (-0.49 to 0.02)‡‡ -0.11 (-0.30 to 0.08)
% Macrophages B (95% CI) 0.22 (<0.01 to 0.43)* 0.28 (0.01 to 0.56)* 0.28 (-0.01 to 0.56)‡ 0.15 (-0.07 to 0.36)
% Eosinophils# B (95% CI) 0.22 (-4.0–4.5) -0.73 (-6.13–4.67) 2.42 (-3.27–8.10) -0.61 (-4.80–3.58)
The univariate association between SGRQ scores (dependent) and sputum cell counts (independent) was expressed by regression coefficient B 
with corresponding 95% confidence intervals (95% CI). The regression coefficient B represents the strength of the association. Our results show 
that an increase in sputum macrophages of 1% is associated with an increase of the mean total score of 0.22 point, indicating that an increase in 
sputum macrophages of 20% is associated with an increase of the mean total score of 4.4 points, which exceeds the clinically relevant threshold of 
four units in SGRQ scores. †Total cell count was logtransformated; # % eosinophils were transformed using the square root. *p ≤ 0.05, ‡p = 0.061, 
‡‡p = 0.068.
ine receptor 2 (CCR2), have been implicated in the
recruitment of macrophages into the bronchiolar epithe-
lium in COPD [38]. These macrophages can release a large
variety of inflammatory cytokines such as tumor necrosis
factor (TNF-α), IL-8, CXC-chemokines, LTB4, and reactive
oxygen species that are likely to drive airway inflamma-
tion in COPD. Moreover they produce elastolytic
enzymes, e.g. metalloproteinases [39,40] such as macro-
phage elastase (MME), that may degrade the extracellular
matrix and thus contribute to the development of paren-
Relationship between percentages macrophages in induced sputum (x-axis) and SGRQ scores (y-axis) (n = 102) Figure 1
Relationship between percentages macrophages in induced sputum (x-axis) and SGRQ scores (y-axis) (n = 102). Results form 
linear regression analyses (B and 95% confidence interval).
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chymal damage and thereby to pulmonary emphysema in
COPD [13,36,41].
The novelty of this study is that associations were
observed between health status and local airways inflam-
mation, whilst previous studies suggested associations
between impaired health status and systemic inflamma-
tion in COPD [14,42]. Previously, it has been suggested
that the systemic inflammatory response may be due to a
overflow of pulmonary mediators from the airways [14].
However, Vernooy et al. showed that soluble tumour
necrosis factor receptor (sTNF-R) and IL8 in sputum and
plasma were not correlated, suggesting that the inflamma-
tory process in the local and systemic compartment are
regulated differentially [43,44]. In the airways neu-
trophilic inflammation is associated with lower FEV1 lev-
els in COPD [45]. The role of airway macrophages may be
linked to different pathophysiological processes as men-
tioned above. Environmental exposures such as tobacco
smoke may promote macrophage-induced alveolar dam-
age [46], leading to impaired alveolar-capillary gastrans-
port and accompanying changes in health status.
Interestingly, our results are suggestive of a distinct role
for the differential cell counts rather than the total
amount of macrophages. Taken together, we may specu-
late that the local and systemic inflammatory responses
are partly differentially regulated, mutually determining
the COPD phenotype. If so, this will be of major impor-
tance when developing effective interventions in this dis-
ease.
The percentage macrophages in sputum was associated
with the SGRQ total score (a summary measure of health
status), as well as the SGRQ symptom score (severity of
symptoms) and SGRQ activity score (physical activities
that cause or are limited by breathlessness). As shown in
figure 1, the differences in health status between patients
with relatively higher and lower percentages of macro-
phages can be considered as clinically relevant, because
they reached the clinically significant threshold of four
units in SGRQ scores [27]. This suggests that airway
inflammation in COPD is relevant for disease outcome in
daily life. Inflammatory cell counts in sputum were not
associated with the impact score. This score measures
social and psychological effects of the disease, such as anx-
iety and coping, and it is plausible that this score is less
influenced by the inflammatory component of the dis-
ease. It is important to notice that only a limited part of
health status could be explained by the severity of airway
inflammation. The likely reason for this is that a wide
spectrum of disease processes potentially affects health
status [4]. Furthermore, other factors such as coping or the
presence and frequency of exacerbations might also play
an additional role in its impairment in patients with
COPD [47].
We observed a consistent and independent contribution
of hyperinflation on health status in patients with mild to
moderate COPD. This is in line with a previous study,
where hyperinflation was associated with poor health sta-
tus in very severe patients with COPD who were using
long-term oxygen treatment [48]. Hyperinflation causes
an increase in lung volume with a concomitant increase of
work of breathing, functional impairment of inspiratory
muscle function, and adverse effects on haemodynamics
which all may contribute to dyspnea [49]. In a recent
study in COPD tiotropium bromide significantly
decreased the residual volume [7], which was correlated
with a decrease in dyspnea. This is indicative of the clini-
cal relevance of hyperinflation in COPD, and the more so
because dyspnea appears to be an important factor influ-
encing health status [50]. In addition, the activity score
measures physical activities that on the one hand induce
breathlessness, and on the other may become limited by
this particular symptom. Therefore, the current associa-
tions between hyperinflation and various domains of
health status are not unexpected.
In conclusion, we have observed that a worse health status
in COPD is significantly associated with higher inflamma-
tory cell counts in induced sputum, whereas only margin-
ally additional contributions were found for lung
function measures reflecting hyperinflation. Our observa-
tion that airway inflammation negatively affects health
status of COPD patients may have clinical relevance. At
present, anti-inflammatory therapy with inhaled corticos-
teroids is a recommended treatment option in patients
with advanced COPD [2]. This has been shown to reduce
deterioration in health status [5,51]. If health status is
partly driven by the local inflammatory process in COPD
this may provide a rationale for the usage of anti-inflam-
matory therapy in COPD. It now needs to be examined
whether the severity of airway inflammation predicts the
benefits of long-term anti-inflammatory intervention on
health status in COPD.
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